Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2017-07-12 |
Pierre Fabre (France) |
|
|
opening of new premises |
Consumer Health Care |
Opening of new premises |
2017-07-12 |
Enterome Bioscience (France) |
|
|
nomination |
|
Nomination |
2017-07-12 |
Daiichi Sankyo (Japan) Max Planck Innovation (Germany) the Lead Discovery Center (Germany) |
new lead compound for the treatment of cancer |
|
licensing |
Cancer - Oncology |
Licensing agreement |
2017-07-12 |
Enterome Bioscience (France) |
non-executive director |
|
nomination |
Liver diseases - Hepatic diseases - Inflammatory diseases - Digestive diseases |
Nomination |
2017-07-11 |
Poxel (France) |
|
|
nomination |
Metabolic diseases |
Nomination |
2017-07-11 |
Enterome Bioscience (France) Nestlé Health Science (Switzerland) Microbiome Diagnostics Partners |
|
inflammatory bowel diseases, liver diseases. |
joint-venture agreement |
Liver diseases - Hepatic diseases - Inflammatory diseases |
Joint-venture agreement |
2017-07-10 |
PCI Biotech (Norway) undisclosed top-10 large pharma company |
fimaNAc technology (nucleic acid therapeutics delivery) |
|
R&D - research |
undisclosed |
Research agreement |
2017-07-10 |
Crispr Therapeutics (Switzerland - UK) Neon Therapeutics (USA - MA) |
T cell therapies |
|
research |
Cancer - Oncology |
Research agreement |
2017-07-10 |
BioInvent (Sweden) Thrombogenics (Belgium) |
TB-403, THR-317 |
|
licensing |
Cancer - Oncology - Ophtalmological diseases |
Licensing agreement |
2017-07-07 |
Relief Therapeutics (Switzerland) |
|
|
resignation |
|
Resignation |
2017-07-07 |
Immunocore (UK) |
|
|
construction of new premises |
Autoimmune diseases – Cancer - Oncology - Infectious diseases |
Construction of new premises |
2017-07-06 |
Novartis (Switzerland) Conatus Pharmaceuticals (USA - CA) |
emricasan |
NASH (non-alcoholic steatohepatitis) and chronic liver diseases |
development - licensing - commercialisation |
Hepatic diseases - Liver diseases |
Exercise of an option agreement |
2017-07-06 |
Novartis (Switzerland) Oxford Biomedica (UK) |
lentiviral vectors used to generate CTL019 (tisagenlecleucel) and other undisclosed Chimeric Antigen Receptor T cell (CART) products |
|
production - manufacturing |
Cancer - Oncology - Technology - Services |
Production agreement |
2017-07-06 |
Eli Lilly (USA - IN) Purdue University (USA - IN) |
|
pain |
collaboration |
CNS diseases |
Collaboration agreement |
2017-07-05 |
Coherus Biosciences (USA - CA) Daiichi Sankyo (Japan) |
biosimilar forms of etanercept (CHS-0214 ) and rituximab |
|
development - commercialisation |
|
Development agreement |
2017-07-05 |
Horizon Discovery (UK) |
novel transposon-based gene editing technology platform |
|
licensing |
Technology - Services |
Licensing agreement |
2017-07-04 |
Sun Pharmaceutical Industries (India) Samsung BioLogics (Republic of Korea) |
tildrakizumab |
|
manufacturing - bioproduction |
|
Production agreement |
2017-07-04 |
Sagetis Biotech (Spain) |
member of the scientific advisory board |
|
nomination |
Cancer - Oncology - Rare diseases |
Nomination |
2017-07-03 |
Immunocore (UK) GSK (UK) |
multiple novel targets not addressable using antibody-based technologies |
undisclosed |
research - development - licensing |
Cancer - Oncology |
Milestone |
2017-07-03 |
Bayer Healthcare (Germany) |
|
|
construction of new premises |
Veterinary medicine |
Construction of new premises |